Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically filed in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction and does not contain financial performance data.
Material Changes
The filing details a change in shareholding for Dr. P J T Vallance, a Person Discharging Managerial Responsibilities. On October 8, 2015, GSK was advised that Dr. Vallance's Connected Person, Dr. S Dexter, acquired 314 GSK Ordinary Shares. This acquisition occurred at a price of 1,286.50 pence per share following the re-investment of the dividend paid to shareholders on October 1, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction noted above.
Investor Verification Checklist
- Verify the total shareholding of Dr. P J T Vallance and Dr. S Dexter following this transaction.
- Confirm the dividend reinvestment plan terms applicable to the October 1, 2015 dividend.
- Review the share price of 1,286.50 pence against the market price on the transaction date.